TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: CCR4 occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Enamel damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite residue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LAG (Loss of Adhesive Gaps)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of total and high‐molecular weight (HMW) adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of work-related childhood agricultural injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Release of myocardial enzymes (CK, CK-MB, LDH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Good or intermediate outcome on the Morgan‐Russell scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinically significant gains in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in mood and eating disorder psychopathology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Detection of markers of myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postprocedural peak markers levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacokinetics of carisbamate IR formulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety and tolerability of carisbamate
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rutherford class improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VascuQoL score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Use of HEDIS codes for BMI percentile documentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of HEDIS codes for counseling for nutrition or physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of PSQI score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: HAMD reduction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAMA reduction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD fluid CA125 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum TBG concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: TWSI (Treatment-Resistant Suicidal Ideation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PBI global score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EQ VAS score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: neuronal expression of lipocalin-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: glial activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: prorecovery phenotypes of microglia and astrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood flow ≥ 300 ml/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of prostate cancer (PC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: mean peak LDL diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: frequency of LDL phenotype A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Eligible time to discharge from the CRU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PES values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma peptide F (P-F) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in post-dose QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of attendance
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Sitting Systolic Blood Pressure (SBP) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-h Systolic Blood Pressure variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in Schirmer score ≥10 mm from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent change in global SANDE scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: peri-implant tissue changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA methylation of promoter-specific regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skin extensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: disability index improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: vitality subscale improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Negative mycologic culture at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall mycologic cure rate at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dyspnea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients requiring re-excision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Specimen weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of medical decisions made without available or applicable evidence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: amelioration of sex symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in skeletal muscle TNF-alpha protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in maximum oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in fasting plasma insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in evaluation tool scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile (minor complications)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of infants with antibody ≥0.35 μg/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: OPA GMTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 7 day mortality
Endpoint domain: Mortality/survival
Primary endpoint: neonatal intensive care unit mortality
Endpoint domain: Mortality/survival
Primary endpoint: peer ratings of aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: observed verbal aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total antioxidant capacity of GCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean correct scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change from baseline in MADRS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients completing the study
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of urinary incontinence (UI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of urinary incontinence (UI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of urinary incontinence (UI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digit symbol substitution test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Regulation of tympanic temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants above established cut points indicative of low CRF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IgA levels against oats
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma volume after exercise to exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dye leakage at margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of endoscopies performed
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Cost of surveillance strategy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Transient positive diagnoses of dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motion exposure time required to produce moderate nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-way endpoint at 96 h
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in DASH values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IL-4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: overall costs of total hip arthroplasty surgery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Oozing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self‐recorded seasonal allergic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in nasal symptoms following nasal allergen provocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suppression of dental plaque formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DIS score for hypersensitive teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hypersensitive teeth free of sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral pain
Endpoint domain: Adverse events/effects
Primary endpoint: Tcore preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPO maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reaction time cost to fearful and neutral faces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean bioavailability of M6G
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean elimination half-life of M6G
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean clearance of M6G
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of cancer
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in dentoalveolar relationships
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in facial expressions during lip pucker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in facial expressions during maximal mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain during insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hope for survival
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percentage of infections per urine sample
Endpoint domain: Adverse events/effects
Primary endpoint: breast cancer overall survival
Endpoint domain: Mortality/survival
Primary endpoint: 22 h glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: nocturnal mean glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: waking glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lower risk of infection with dengue virus in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: fewer reports of dengue illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: fewer houses with larvae or pupae (house index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: White-matter volume loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decreased glucose uptake in the cortex and striatum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of preterm birth (PTB) at <35 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of antiphosphatidylinositol immunoglobulin G
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunoglobulin M levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: C4 and C3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sarcopenia index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients losing 10% of initial weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average BMI change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stillbirth
Endpoint domain: Mortality/survival
Primary endpoint: Adhesion formation around the stoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increased mammary epithelial permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrinkle Severity Rating Scale (WSRS) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anaerobic energy expenditure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance output (PO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Richmond Agitation and Sedation Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients requiring additive sedatives
Endpoint domain: Adverse events/effects
Primary endpoint: Erosion of dentine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abrasion of dentine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UV-induced erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Greater insulin sensitivity in hyperglycemic conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lower HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total vaginal length
Endpoint domain: Physiological/clinical
Primary endpoint: quality of recovery (QoR-40)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: stress-induced hypoperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tumor necrosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprocedural troponin T elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postprocedural myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-treatment TG level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-treatment HDL level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left atrial maximum and minimum volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective comfort with VSD and ToF
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postlecture test scores for ToF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for SOS manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity and incidence of postoperative hoarseness
Endpoint domain: Adverse events/effects
Primary endpoint: Severity and incidence of sore throat
Endpoint domain: Adverse events/effects
Primary endpoint: Change in health state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unplanned GP visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Planned GP visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in mastication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in general satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: central visual function (CS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of oral herpes
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction with the training programme
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: binge-eating episodes/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sleep time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: sleep fragmentation
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: new bulla formation cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steroid tapering duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Vh:Cd
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase in IELs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase in antibody titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IMCL_CH2/Cr and IMCL_CH3/Cr ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: teacher-reported social skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: A-aDO2 change after extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: frequency of refractory seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: duration of refractory seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clot lysis time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: upadacitinib Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upadacitinib AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerability of upadacitinib
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of time with RI<20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative alfentanil use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative propofol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to postanesthesia care unit discharge readiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of severe postoperative pain
Endpoint domain: Adverse events/effects
Primary endpoint: Optic Nerve Head Perfusion Assessment (OPA) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: strut-coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Anti-irritant effect of glycerol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occupational performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total bacterial reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dietary behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PDI motor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of tamsulosin and naftopidil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes